Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Wal-Mart Testing Direct Pharmacy Price Negotiation With Employer Plan

Executive Summary

Wal-Mart is negotiating pharmacy prices directly with the employee health plan operated by construction equipment manufacturer Caterpillar in a pilot program scheduled to run through 2009

You may also be interested in...

Employer Insurance Alliance May Test New PBM Contracting Approaches

Pilot project will launch in 2017, aiming to share data and best practices to control health care costs and create better outcomes.

Wal-Mart Plans Rx Cost-Management Initiative In 2008 To Save Up To $100 Million

Wal-Mart plans prescription drug claims management initiative with a select number of employers in 2008.

Keytruda, Opdivo May Be Only Part B Drugs Chosen For Medicare Negotiation In First Applicable Year

In general, more Part D drugs will be eligible than Part B drugs in the early years of the program because Part D drugs have higher levels of spending and so will dominate the list of candidates. A new report sizes up the drugs that would qualify for Medicare Price negotiation in 2026-2028.

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts